- |||||||||| lademirsen (RG-012) / Regulus Therapeutics
Trial completion date, Trial termination, Trial primary completion date: HERA: Study of Lademirsen (SAR339375) in Patients With Alport Syndrome (clinicaltrials.gov) - Oct 17, 2022
P2, N=43, Terminated,
Trial completion date: Dec 2023 --> Sep 2022 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2023 --> Sep 2022; The results of the futility analysis led to the study termination. No unexpected safety findings were identified.
- |||||||||| lademirsen (RG-012) / Regulus Therapeutics, Sanofi, recombinant human pentraxin-2 (RG6354) / Roche, Kerendia (finerenone) / Bayer
Review, Journal: Antifibrotic Agents for the Management of CKD: A Review. (Pubmed Central) - Jul 28, 2022
Reversing dysfunctional tubular cell metabolism that leads to kidney fibrosis offers additional therapeutic opportunities. However, any future drug targeting fibrosis of the kidneys should demonstrate added benefit to a novel standard of care combining renin-angiotensin system with mineralocorticoid receptor (e.g. finerenone) blockade or with SGLT2 inhibitors.
- |||||||||| lademirsen (RG-012) / Regulus Therapeutics, Sanofi, Xenical (orlistat) / Roche, GSK
Journal: Computational analysis of marine algal compounds for obesity management against pancreatic lipase. (Pubmed Central) - May 17, 2022
BC010 complex revealed a stable interaction within the binding pocket and the binding free energy is -158.208 kJ/mol which is higher when compared to other complexes in 100 ns simulation. BC010 ((7S,11S,12S,14R)-4',14-dimethoxyamentol) from brown algae Cystophora fibrosa could be considered as a potential drug candidate to suppress obesity by inhibiting pancreatic lipase.Communicated by Ramaswamy H. Sarma.
- |||||||||| Review, Journal: Novel Therapies for Alport Syndrome. (Pubmed Central) - May 14, 2022
Our review will include bardoxolone methyl, an oral NRf2 activator; lademirsen, an anti-miRNA-21 molecule; sparsentan, dual endothelin type A receptor (ETAR) and angiotensin 1 receptor inhibitor; atrasentan, oral selective ETAR inhibitor; lipid-modifying agents, including cholesterol efflux transporter ATP-binding cassette A1 (ABCA1) inducers, discoidin domain receptor 1 (DDR1) inhibitors and osteopontin blocking agents; the antimalarial drug hydroxychloroquine; the antiglycemic drug metformin and the active vitamin D analog paricalcitol. Future genomic therapeutic strategies such as chaperone therapy, genome editing and stem cell therapy will also be discussed.
- |||||||||| lademirsen (RG-012) / Regulus Therapeutics, Sanofi
Preclinical, Journal: Anti-microRNA-21 Therapy on Top of ACE Inhibition Delays Renal Failure in Alport Syndrome Mouse Models. (Pubmed Central) - Apr 9, 2022
Here, we investigated the nephroprotective effects of Lademirsen anti-miR-21 therapy...In conclusion, significant additive effects were detected for the combination of anti-miR-21 and ACEi therapies on kidney function, pathology and survival in Alport mouse models, as well as a strong differential effect of anti-miR-21 on the renal expression of fibrotic factors. These results support the addition of anti-miR-21 to the current standard of care (ACEi) in ongoing clinical trials in patients with Alport syndrome.
- |||||||||| lademirsen (RG-012) / Regulus Therapeutics
Enrollment closed: HERA: Study of Lademirsen (SAR339375) in Patients With Alport Syndrome (clinicaltrials.gov) - Feb 10, 2022
P2, N=43, Active, not recruiting,
These results support the addition of anti-miR-21 to the current standard of care (ACEi) in ongoing clinical trials in patients with Alport syndrome. Recruiting --> Active, not recruiting
- |||||||||| lademirsen (RG-012) / Regulus Therapeutics
Trial completion date, Trial primary completion date: HERA: Study of Lademirsen (SAR339375) in Patients With Alport Syndrome (clinicaltrials.gov) - Dec 8, 2021
P2, N=45, Recruiting,
Recruiting --> Active, not recruiting Trial completion date:Aug 2027 --> Dec 2023 | Trial primary completion date: Aug 2027 --> Dec 2023
- |||||||||| lademirsen (RG-012) / Regulus Therapeutics
Trial completion date, Trial primary completion date: HERA: Study of Lademirsen (SAR339375) in Patients With Alport Syndrome (clinicaltrials.gov) - Dec 1, 2021
P2, N=45, Recruiting,
Trial completion date:Aug 2027 --> Dec 2023 | Trial primary completion date: Aug 2027 --> Dec 2023 Trial completion date: Dec 2023 ->Aug 2027 | Trial primary completion date: Dec 2023 --> Aug 2027
- |||||||||| lademirsen (RG-012) / Regulus Therapeutics
Trial completion date, Trial primary completion date: HERA: Study of Lademirsen (SAR339375) in Patients With Alport Syndrome (clinicaltrials.gov) - Nov 19, 2021
P2, N=45, Recruiting,
Trial completion date: Dec 2023 ->Aug 2027 | Trial primary completion date: Dec 2023 --> Aug 2027 Trial completion date: Aug 2027 --> Dec 2023 | Trial primary completion date: Aug 2027 --> Dec 2023
- |||||||||| lademirsen (RG-012) / Regulus Therapeutics
Trial completion date, Trial primary completion date: HERA: Study of Lademirsen (SAR339375) in Patients With Alport Syndrome (clinicaltrials.gov) - Nov 18, 2021
P2, N=45, Recruiting,
Trial completion date: Aug 2027 --> Dec 2023 | Trial primary completion date: Aug 2027 --> Dec 2023 Trial completion date: Dec 2023 --> Aug 2027 | Trial primary completion date: Dec 2023 --> Aug 2027
- |||||||||| lademirsen (RG-012) / Regulus Therapeutics
Trial completion date, Trial primary completion date: HERA: Study of Lademirsen (SAR339375) in Patients With Alport Syndrome (clinicaltrials.gov) - Sep 27, 2021
P2, N=45, Recruiting,
Trial completion date: Dec 2023 --> Aug 2027 | Trial primary completion date: Dec 2023 --> Aug 2027 Trial completion date: Jun 2023 --> Dec 2023 | Trial primary completion date: Jun 2023 --> Dec 2023
- |||||||||| lademirsen (RG-012) / Regulus Therapeutics
Enrollment open, Trial completion date, Trial primary completion date: HERA: Study of Lademirsen (SAR339375) in Patients With Alport Syndrome (clinicaltrials.gov) - Jul 8, 2019
P2, N=45, Recruiting,
Recruiting --> Suspended Suspended --> Recruiting | Trial completion date: Dec 2019 --> Mar 2023 | Trial primary completion date: Dec 2019 --> Mar 2023
- |||||||||| lademirsen (RG-012) / Regulus Therapeutics, Sanofi
Trial completion: A Study of RG-012 in Subjects With Alport Syndrome (clinicaltrials.gov) - May 24, 2019
P1, N=4, Completed,
Suspended --> Recruiting | Trial completion date: Dec 2019 --> Mar 2023 | Trial primary completion date: Dec 2019 --> Mar 2023 Active, not recruiting --> Completed
- |||||||||| lademirsen (RG-012) / Regulus Therapeutics, Sanofi
Enrollment change, Trial completion date, Trial primary completion date: A Study of RG-012 in Subjects With Alport Syndrome (clinicaltrials.gov) - Nov 20, 2018
P1, N=4, Active, not recruiting,
Recruiting --> Suspended N=10 --> 4 | Trial completion date: Sep 2019 --> Mar 2019 | Trial primary completion date: Sep 2018 --> Mar 2019
- |||||||||| lademirsen (RG-012) / Regulus Therapeutics, Sanofi
Enrollment closed: A Study of RG-012 in Subjects With Alport Syndrome (clinicaltrials.gov) - Jul 9, 2018
P1, N=10, Active, not recruiting,
N=10 --> 4 | Trial completion date: Sep 2019 --> Mar 2019 | Trial primary completion date: Sep 2018 --> Mar 2019 Recruiting --> Active, not recruiting
- |||||||||| lademirsen (RG-012) / Regulus Therapeutics, Sanofi
Trial completion date, Trial primary completion date: A Study of RG-012 in Subjects With Alport Syndrome (clinicaltrials.gov) - Apr 2, 2018
P1, N=10, Recruiting,
Recruiting --> Active, not recruiting Trial completion date: Dec 2018 --> Sep 2019 | Trial primary completion date: Feb 2018 --> Sep 2018
|
